New article out soon on SIBO and probiotics

I really enjoyed writing the article on small intestinal bacterial overgrowth and probiotics; fiend or foe for CN Magazine.
It's always a good opportunity for me to do a deep dive into the evidence behind a purported treatment for gastrointestinal conditions.

What is Small intestinal bacterial overgrowth?
Small intestinal bacterial overgrowth (SIBO) is characterised by either an abnormal increase in the number or type of bacteria (or indeed both), in the small intestine. 
This occurs in the duodenum and jejunum, not designed to host a high microbial load.
SIBO is commonly associated with gastrointestinal (GI) symptoms including bloating, abdominal pain, flatulence, diarrhoea or constipation. Symptoms can occur because of the newly colonised Gram-negative aerobic and anaerobic species (usually found in the colon), feeding off sugars and fermentable carbohydrate, producing methane, carbon dioxide and hydrogen.

In this article I look at what SIBO is, how it is diagnosed and what the risk factors are for this condition, and how it is traditionally treated. The evidence base behind the use of probiotics with SIBO is inconsistent. I found some clinical trials were for and against the use to support improvement in symptoms. I do reference some probiotics that have had promising results. So look out for this article when it is published shortly in CN Magazine.